at zynerba pharmaceuticals (nasdaq: zyne), we are dedicated to developing next-generation synthetic cannabinoid therapeutics for transdermal delivery for patients with significant unmet medical needs. our mission is to improve the lives of patients battling severe health conditions including refractory epilepsy, osteoarthritis, fragile x syndrome, fibromyalgia and peripheral neuropathic pain through these therapeutics. our development pipeline includes patent-protected synthetic transdermal cannabinoid products, cbd gel – zyn002 and thc pro-drug patch – zyn001, which we believe will provide new treatment options for patients as well as additional treatment options for patients not currently receiving adequate relief or otherwise experiencing intolerable side effects from current treatment regimes.
Company profile
Ticker
ZYNE
Exchange
Website
CEO
Armando Anido
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
Zynerba Pharmeceuticals, Inc.
SEC CIK
Corporate docs
Subsidiaries
Zynerba Pharmaceuticals Pty Ltd ...
ZYNE stock data
Latest filings (excl ownership)
15-12G
Securities registration termination
19 Oct 23
EFFECT
Notice of effectiveness
12 Oct 23
POS AM
Prospectus update (post-effective amendment)
11 Oct 23
S-8 POS
Registration of securities for employees (post-effective amendment)
11 Oct 23
S-8 POS
Registration of securities for employees (post-effective amendment)
11 Oct 23
S-8 POS
Registration of securities for employees (post-effective amendment)
11 Oct 23
S-8 POS
Registration of securities for employees (post-effective amendment)
11 Oct 23
S-8 POS
Registration of securities for employees (post-effective amendment)
11 Oct 23
S-8 POS
Registration of securities for employees (post-effective amendment)
11 Oct 23
S-8 POS
Registration of securities for employees (post-effective amendment)
11 Oct 23
Transcripts
Latest ownership filings
SC 13G/A
Beryl Capital Management LLC
8 Feb 24
4
Kenneth T Jones
11 Oct 23
4
Pamela Stephenson
11 Oct 23
4
James E Fickenscher
11 Oct 23
4
Terri B Sebree
11 Oct 23
4
WILLIAM J FEDERICI
11 Oct 23
4
Brian Rosenberger
11 Oct 23
4
WARREN D COOPER
11 Oct 23
4
Albert P Parker
11 Oct 23
4
John P. Butler
11 Oct 23
Financial summary
Quarter (USD) | Jun 23 | Mar 23 | Dec 22 | Sep 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 35.97 mm | 35.97 mm | 35.97 mm | 35.97 mm | 35.97 mm | 35.97 mm |
Cash burn (monthly) | 2.81 mm | 2.21 mm | 3.71 mm | 3.23 mm | 2.81 mm | 2.64 mm |
Cash used (since last report) | 25.15 mm | 19.77 mm | 33.21 mm | 28.92 mm | 25.11 mm | 23.59 mm |
Cash remaining | 10.82 mm | 16.19 mm | 2.75 mm | 7.05 mm | 10.86 mm | 12.38 mm |
Runway (months of cash) | 3.8 | 7.3 | 0.7 | 2.2 | 3.9 | 4.7 |
Institutional ownership, Q3 2023
35.4% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 44 |
Opened positions | 19 |
Closed positions | 16 |
Increased positions | 3 |
Reduced positions | 11 |
13F shares | Current |
---|---|
Total value | 13.16 bn |
Total shares | 19.10 mm |
Total puts | 18.30 k |
Total calls | 0.00 |
Total put/call ratio | Infinity |
Largest owners | Shares | Value |
---|---|---|
HRMY Harmony Biosciences | 7.59 mm | $0.00 |
Beryl Capital Management | 4.90 mm | $6.25 bn |
Highbridge Capital Management | 2.28 mm | $2.91 bn |
Yakira Capital Management | 620.02 k | $790.52 mm |
Renaissance Technologies | 605.70 k | $772.00 k |
CSS | 476.83 k | $607.96 mm |
Deltec Asset Management | 475.00 k | $605.63 mm |
Millennium Management | 325.24 k | $413.05 mm |
Jane Street | 282.48 k | $360.16 mm |
Crystalline Management | 230.82 k | $294.29 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
10 Oct 23 | Kisner Daniel L | Common Stock | Dispose U | No | No | 0 | 47,824 | 0.00 | 0 | |
10 Oct 23 | Kisner Daniel L | Common Stock | Dispose U | No | No | 0 | 27,954 | 0.00 | 47,824 | |
10 Oct 23 | Kisner Daniel L | Stock Option Common Stock | Sale back to company | Dispose D | No | No | 0.3501 | 71,736 | 25.11 k | 0 |
10 Oct 23 | Kisner Daniel L | Stock Option Common Stock | Sale back to company | Dispose D | No | No | 1.01 | 34,663 | 35.01 k | 0 |
10 Oct 23 | Anido Armando | Common Stock | Dispose U | Yes | No | 0 | 13,297 | 0.00 | 0 | |
10 Oct 23 | Anido Armando | Common Stock | Dispose U | Yes | No | 0 | 26,595 | 0.00 | 0 | |
10 Oct 23 | Anido Armando | Common Stock | Dispose U | No | No | 0 | 610,000 | 0.00 | 0 | |
10 Oct 23 | Anido Armando | Common Stock | Grant | Acquire A | No | No | 0 | 240,000 | 0.00 | 610,000 |
10 Oct 23 | Anido Armando | Common Stock | Dispose U | No | No | 0 | 566,722 | 0.00 | 370,000 | |
10 Oct 23 | Anido Armando | Stock Option Common Stock | Sale back to company | Dispose D | No | No | 2.41 | 190,000 | 457.90 k | 0 |